Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies

Antibody therapeutics and vaccines for coronavirus disease 2019 (COVID-19) have been approved in many countries, with most being developed based on the original strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 has an exceptional ability to mutate under the pressure...

Descripción completa

Detalles Bibliográficos
Autores principales: Ling, Zhiyang, Yi, Chunyan, Sun, Xiaoyu, Yang, Zhuo, Sun, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Science China Press 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707277/
https://www.ncbi.nlm.nih.gov/pubmed/36443513
http://dx.doi.org/10.1007/s11427-022-2215-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707277/
https://www.ncbi.nlm.nih.gov/pubmed/36443513
http://dx.doi.org/10.1007/s11427-022-2215-6

Ejemplares similares